Erlotinib indications were updated again in 2016 with the publication of the IUNO trial, which demonstrated no survival benefit in EGFR wild-type individuals, and currently erlotinib is only approved in NSCLC for patients with an EGFR mutation [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.